A practical reference on angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-19. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
=== Metabolites === Metabolites are the substances (generally waste products) produced as a result of muscular contraction. They include chloride, potassium, lactic acid, ADP, magnesium (Mg2+), reactive oxygen species, and inorganic phosphate. Accumulation of metabolites can directly or indirectly produce metabolic fatigue within muscle fibers through interference with the release of calcium (Ca2+) from the sarcoplasmic reticulum or reduction of the sensitivity of contractile molecules actin and myosin to calcium.
== Other Activities == 1972–1975 – Associate Member, Viking Lander Science Team, NASA 1979–1982 – – Member, Committee on Response Strategies to Unusual Chemical Hazards, Assembly of Life Sciences, National Research Council 1982 – U.S. Coordinator, U.S.-Japan Joint Seminar on “Microcolumn Separation Methods and their Ancillary Techniques,” Honolulu, Hawaii 1980–1984 – Member, Advisory Committee to the Analytical Chemistry Division, Oak Ridge National Laboratory 1986 – Instructor, ACS Short Course on Supercritical Fluid Chromatography 1988, 1990 – Organizing Committee, International Symposium, “Microcolumn Separation Methods,” Bloomington, IN and Aronberg, Sweden 1988, 1991 – Scientific Committee, International Symposium, “HPLC 88” and “HPLC 92” 1977–Pres. – Instructor, ACS Short Course on Capillary Gas Chromatography 1978–Pres. – ACS Lecture Tour Speaker 1990–Pres. – Scientific Committee, International Symposia on Capillary Chromatography 1994 – Scientific Committee, Glycobiology: Analytical Methods 2003 – Member of the Center for the Integrative Study of Animal Behavior, Indiana University 2004 – Member of the Indiana University Cancer Center, IU School of Medicine .
Of great importance to the model building effort of Watson and Crick was Rosalind Franklin's understanding of basic chemistry, which indicated that the hydrophilic phosphate-containing backbones of the nucleotide chains of DNA should be positioned so as to interact with water molecules on the outside of the molecule while the hydrophobic bases should be packed into the core. Franklin shared this chemical knowledge with Watson and Crick when she pointed out to them that their first model (from 1951, with the phosphates inside) was obviously wrong. Crick described what he saw as the failure of Wilkins and Franklin to cooperate and work towards finding a molecular model of DNA as a major reason why he and Watson eventually made a second attempt to do so. They asked for, and received, permission to do so from both William Lawrence Bragg and Wilkins. To construct their model of DNA, Watson and Crick made use of information from unpublished X-ray diffraction images of Franklin's (shown at meetings and freely shared by Wilkins), including preliminary accounts of Franklin's results/photographs of the X-ray images that were included in a written progress report for the King's College laboratory of Sir John Randall from late 1952. It is a matter of debate whether Watson and Crick should have had access to Franklin's results without her knowledge or permission, and before she had a chance to formally publish the results of her detailed analysis of her X-ray diffraction data which were included in the progress report.
Sources: en.wikipedia.org
Upon activation, bAREs ADP-ribosylate any number of eukaryotic proteins; such mechanism is crucial to the instigation of the diseased states associated with ADP-ribosylation. GTP-binding proteins, in particular, are well-established in bAREs pathophysiology. For examples, cholera and heat-labile enterotoxin target the α-subunit of Gs of heterotrimeric GTP-binding proteins. As the α-subunit is ADP-ribosylated, it is permanently in an "active", GTP-bound state; subsequent activation of intracellular cyclic AMP stimulates the release of fluid and ions from intestinal epithelial cells. Furthermore, C. Botulinum C3 ADP-ribosylates GTP-binding proteins Rho and Ras, and Pertussis toxin ADP-ribosylates Gi, Go, and Gt. Diphtheria toxin ADP-ribosylates ribosomal elongation factor EF-2, which attenuates protein synthesis. There are a variety of bacteria which employ bAREs in infection: CARDS toxin of Mycoplasma pneumoniae, cholera toxin of Vibrio cholerae; heat-labile enterotoxin of E. coli; exotoxin A of Pseudomonas aeruginosa; pertussis toxin of B. pertussis; C3 toxin of C. botulinum; and diphtheria toxin of Corynebacterium diphtheriae.
This charge polarization within the molecule allows it to align with adjacent molecules through strong intermolecular hydrogen bonding, rendering the bulk liquid cohesive. Van der Waals gases such as methane, however, have weak cohesion due only to van der Waals forces that operate by induced polarity in non-polar molecules. Cohesion, along with adhesion (attraction between unlike molecules), helps explain phenomena such as meniscus, surface tension, and capillary action. Mercury in a glass flask is a good example of the effects of the ratio between cohesive and adhesive forces. Because of its high cohesion and low adhesion to the glass, mercury does not spread out to cover the bottom of the flask, and if enough is placed in the flask to cover the bottom, it exhibits a strongly convex meniscus, whereas the meniscus of water is concave. Mercury will not wet the glass, unlike water and many other liquids, and if the glass is tipped, it will 'roll' around inside.
15 episodes Rick Stein's Cornwall, Series 2, BBC Two, 2022. 15 episodes Rick Stein's Cornwall, Series 3, BBC Two, 2023. 10 episodes Rick Stein’s Food Stories, BBC Two, February 2024. 15 episodes Rick Stein’s Australia, BBC Two, January 2026. 6 episodes
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.